多发性骨髓瘤患者血清IL-33和IL-6水平的变化及其临床意义

目的 检测多发性骨髓瘤（Multiple myeloma,MM）患者血清中IL-33和IL-6水平,探讨其在疾病发展中的作用.方法 选取2012年1月至2013年1月间37例多发性骨髓瘤患者和50例健康对照者作为研究对象,应用ELISA方法检测所有研究对象血清中IL-33和IL-6水平,并进行统计学分析.结果 两组研究对象的IL-33检出率差异无统计学意义;IL-33水平与MM分期呈负相关,MM患者IL-33水平与健康对照者相比显著降低,其差异具有统计学意义（P＜0.05）; IL-6水平与MM分期呈正相关,MM患者IL-6水平与健康对照者相比显著升高,其差异具有统计学意义（P＜0.05）.结论 MM进展过程中IL-33和IL-6分泌改变可能导致免疫失衡而使疾病逐步恶化,其有助于病情监测和为免疫治疗提供理论依据.

Changes of IL-33 and IL-6 level in patients with multiple myeloma and their clinical significance

Objective To detect the serum levels of IL-33 and IL-6 in patients with multiple myeloma, and to explore their role in disease development. Methods From Jan. 2012 to Jan. 2013, 37 patients of multiple myeloma （MM） and 50 healthy controls were selected as the research objects. ELISA was used to detect the serum levels of IL-33 and IL-6. Data were statistically analyzed. Results The detection rate of IL-33 showed no statistically signifi- cant difference between the two groups. IL-33 levels were negatively correlated with MM stage, and IL-33 levels of MM patients decreased significantly compared with healthy controls （P〈0.05）. IL-6 levels were positively correlated with MM stage, and IL-6 level of MM patients increased significantly compared with healthy controls （P〈 0.05）. Conclusion Changes in IL-33 and IL-6 levels may promote the progress of MM by adjusting the cellular im- munity, and maintaining the balance ofT cell subgroup may contribute to the treatment of myeloma disease.